ENA Respiratory raises US$22.4m in Series B financing to fund Phase II development of INNA-051 nasal spray, with investments from Gates Foundation and Flu Lab.
Amount Raised
$22.4 Million
Round Type
Series B
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalInvestors
Description
ENA Respiratory, a clinical-stage pharmaceutical company, has raised US$22.4m in its Series B financing to develop INNA-051 nasal spray for viral respiratory infections. The round saw participation from new investor Gates Foundation and others like Brandon Capital and Flu Lab. This funding will support a Phase II clinical study to assess the spray's efficacy and safety among participants. The study is set to recruit up to 1,100 participants during the 2025-2026 North American respiratory virus season.
Quick answer
ENA Respiratory raised $22.4 Million in a Series B round, dated October 22, 2025. Investors: Stoic Venture Capital, Uniseed, Brandon Capital, Flu Lab and Gates Foundation. ENA Respiratory is based in Melbourne, Victoria, Australia.
- How much did ENA Respiratory raise?
- ENA Respiratory raised $22.4 Million in a Series B round on October 22, 2025.
- Who invested in ENA Respiratory?
- Stoic Venture Capital, Uniseed, Brandon Capital, Flu Lab and Gates Foundation are named as investors in this round.
- What does ENA Respiratory do?
- ENA Respiratory is a clinical-stage pharmaceutical company focused on developing antiviral host defense immune enhancers.
- Where is ENA Respiratory based and how big is it?
- ENA Respiratory is based in Melbourne, Victoria, Australia. Fundz records about 10 employees.
- Who are the decision-makers at ENA Respiratory?
- Fundz holds 2 contacts at ENA Respiratory. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as ENA Respiratory that raised within 45 days of this round, from Fundz verified event records.
- Axoltis Pharma raised $21M (Series A) on December 2, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.3M on November 28, 2025.
- Pelthos Therapeutics raised $18M on November 6, 2025.
- Acasti raised $4M (Funding Round) on October 23, 2025.
- Minerva Neurosciences raised $200M (Funding Round) on October 21, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
Who to call at ENA Respiratory, and when
A new round usually means ENA Respiratory is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ENA Respiratory raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ENA Respiratory, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ENA Respiratory. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ENA Respiratory raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansENA Respiratory raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.